Radiation Free Chemotherapy for Early Hodgkin Lymphoma

Exclusion Criteria

• •Composite lymphoma or nodular lymphocyte-predominant Hodgkin lymphoma;
• •Bulky disease (Lugano 2014 definition: single or conglomerated nodal mass with the largest diameter measuring 10 or more centimeters);
• •B symptoms;
• •Extra nodal site involved by disease;
• •Female patients who are both lactating and breastfeeding or who have a positive serum pregnancy test during the screening period or a positive pregnancy test on Day 1 before first dose of study drug;
• •Uncompensated diabetes mellitus requiring insulin therapy;
• •Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol;
• •Known human immunodeficiency virus (HIV) infection with a positive search for HIV antigens by immunoblot and/or circulating copies of HIV-RNA;
• •Active hepatitis B with circulating copies of HBV-DNA, or active hepatitis C infection with circulating copies of HCV-RNA;
• •Severely impaired, lung and renal function;
• •Diagnosed or treated for another malignancy within 3 years before the first dose or previously diagnosed with another malignancy and have any evidence of residual disease. Patients with non-melanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection;
• •Active autoimmune disorder in treatment with immunosuppressive drugs
• •A left-ventricular ejection fraction \< 50%;
• •Myocardial infarction within 2 years of study entry.
• •Pregnancy or lactation.